NCT02415907View on ClinicalTrials.gov

Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Healthy
Interventions
DRUG

[ethyl-1-14C]-idalopirdine

120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose

DRUG

[benzyl-7-14C]-idalopirdine

120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose

Trial Locations (1)

Unknown

GB802, Leeds

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02415907 - Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine | Biotech Hunter | Biotech Hunter